Global Factor IX Complex Drug Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Factor IX Complex Drug Market Research Report 2024
Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available.
According to Mr Accuracy reports’s new survey, global Factor IX Complex Drug market is projected to reach US$ 1833.5 million in 2029, increasing from US$ 850 million in 2022, with the CAGR of 11.7% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Factor IX Complex Drug market research.
The market factors is increasing prescription of anticoagulants, especially warfarin, as well as rising prevalence of bleeding disorders. Additionally, PCC offers various advantages over Fresh-frozen plasma and others, making it a more suitable option for life-threatening conditions. Apart from this, active government support for the use of 4-factor PCC products such as Kcentra and positive recommendations are anticipated to provide considerable momentum to the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Factor IX Complex Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
CSL Behring
Grifols
Octapharma
Prothya Biosolutions
Takeda
Segment by Type
Beriplex
Profilnine
Octaplex
Prothromplex
Cofact
Other
Hemophilia B
Acquired Coagulation Factor Deficiency
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Factor IX Complex Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Factor IX Complex Drug market is projected to reach US$ 1833.5 million in 2029, increasing from US$ 850 million in 2022, with the CAGR of 11.7% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Factor IX Complex Drug market research.
The market factors is increasing prescription of anticoagulants, especially warfarin, as well as rising prevalence of bleeding disorders. Additionally, PCC offers various advantages over Fresh-frozen plasma and others, making it a more suitable option for life-threatening conditions. Apart from this, active government support for the use of 4-factor PCC products such as Kcentra and positive recommendations are anticipated to provide considerable momentum to the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Factor IX Complex Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CSL Behring
Grifols
Octapharma
Prothya Biosolutions
Takeda
Segment by Type
Beriplex
Profilnine
Octaplex
Prothromplex
Cofact
Other
Segment by Application
Hemophilia B
Acquired Coagulation Factor Deficiency
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Factor IX Complex Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source